D. Boral Capital Reaffirms “Buy” Rating for NRx Pharmaceuticals (NASDAQ:NRXP)

D. Boral Capital reiterated their buy rating on shares of NRx Pharmaceuticals (NASDAQ:NRXP) in a research report report published on Thursday morning,Benzinga reports. They currently have a $34.00 price objective on the stock.

Several other analysts have also recently commented on NRXP. HC Wainwright began coverage on NRx Pharmaceuticals in a report on Monday, September 8th. They issued a “buy” rating and a $40.00 price target for the company. Zacks Research upgraded NRx Pharmaceuticals to a “hold” rating in a research note on Wednesday, September 10th. Finally, BTIG Research reissued a “buy” rating on shares of NRx Pharmaceuticals in a research note on Monday, August 25th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $34.50.

NRx Pharmaceuticals Trading Up 1.4%

NRXP stock opened at $2.95 on Thursday. The firm has a 50 day moving average of $2.74 and a 200-day moving average of $2.61. The company has a market cap of $58.44 million, a price-to-earnings ratio of -1.32 and a beta of 1.63. NRx Pharmaceuticals has a 12-month low of $1.10 and a 12-month high of $6.01.

NRx Pharmaceuticals (NASDAQ:NRXP) last released its quarterly earnings results on Monday, August 18th. The company reported ($0.98) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.67). Sell-side analysts forecast that NRx Pharmaceuticals will post -1.75 earnings per share for the current fiscal year.

Hedge Funds Weigh In On NRx Pharmaceuticals

Several large investors have recently made changes to their positions in NRXP. Squarepoint Ops LLC acquired a new position in shares of NRx Pharmaceuticals in the 4th quarter valued at $56,000. Millennium Management LLC bought a new position in shares of NRx Pharmaceuticals in the fourth quarter valued at approximately $61,000. Geode Capital Management LLC boosted its stake in NRx Pharmaceuticals by 27.9% during the 2nd quarter. Geode Capital Management LLC now owns 172,255 shares of the company’s stock valued at $562,000 after purchasing an additional 37,598 shares during the period. Finally, Anson Funds Management LP grew its position in NRx Pharmaceuticals by 535.1% in the 1st quarter. Anson Funds Management LP now owns 1,179,061 shares of the company’s stock worth $2,417,000 after purchasing an additional 993,401 shares during the last quarter. Institutional investors own 4.27% of the company’s stock.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.